Alto Neuroscience Class Action Lawsuit Filed Over Misleading Statements Regarding ALTO-100 Treatment

Strategic Insights -

The Rosen Law Firm reminds investors of common stock of Alto Neuroscience, Inc. that a class action lawsuit has been filed over misleading statements regarding the effectiveness of ALTO-100 in treating major depressive disorder.

Key Takeaways:

  • The lawsuit alleges that Alto's initial public offering documents and subsequent statements made by the company's defendants were false and misleading regarding the effectiveness of ALTO-100.
  • The defendants allegedly overstated the clinical, regulatory, and commercial prospects of ALTO-100, leading to a decline in the stock's value when the truth became known.
  • Investors who purchased Alto securities during the class period may be entitled to compensation without paying out-of-pocket fees or costs through a contingency fee arrangement.
  • The lead plaintiff deadline is September 19, 2025, and investors who wish to serve as lead plaintiff must move the court by this date.
  • The Rosen Law Firm has a track record of success in securities class actions and shareholder derivative litigation, and has been ranked as one of the top securities class action firms in the country.
  • Over 438 million dollars were recovered by the Rosen Law Firm for investors in 2019 alone.
  • Laurence Rosen, the firm's founding partner, was named a Titan of Plaintiffs' Bar by law360 in 2020.

Statistics:

  • The class period spanned from February 2, 2024, to October 22, 2024.
  • Alto's stock value declined significantly when the truth about ALTO-100's effectiveness became known.
  • $438 million was recovered by the Rosen Law Firm for investors in 2019.
  • The Rosen Law Firm has secured over $100 million for investors in the past five years.

Sources:

  • Newsfile Corp., "WHY: Rosen Law Firm, a Global Investor Rights Law Firm, Announces | Alto Neuroscience, Inc." (August 25, 2025), available at https://www.newsfilecorp.com/release/263603.
  • The Rosen Law Firm, P.A., "Alto Neuroscience Class Action Lawsuit Filed Over Misleading Statements Regarding ALTO-100 Treatment", available at https://rosenlegal.com/submit-form/?case_id=42321.